Update on the role of topotecan in the treatment of non-small cell lung cancer

Oncologist

Volumn 9, Issue SUPPL. 6, 2004, Pages 43-52

  Stewart, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Combination chemotherapy; Non small cell lung carcinoma; Topotecan; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; TOPOTECAN;

EID: 16644387787     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90006-43     Document Type: Review

References (39)

1. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
2. Manegold C. Chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2001;28(suppl 7): 1-6.
3. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001;1:925-983.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
5. Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
6. Ettinger DS. Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? The Oncologist 2002;7:226-233.
7. Furuse K, Kubota K, Kawahara M et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 1994;11:385-391.
8. Veronesi A, Crivellari D, Magri MD et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996;32A: 1809-1811.
9. Carrato A, Rosell R, Camps C et al. Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer 1997;17:261-269.
10. Wozniak AJ. Single-agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 1999;26(suppl 16):62-66; discussion 71-72.
11. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465.
12. Bennouna J, Monnier A, Riviere A et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 2000;36:1107-1112.
13. Dragnev KH, Rigas JR. Non-platinum-based combination chemotherapy for non-small-cell lung cancer. Lung Cancer Updates 2001;l:l-14.
14. Eckardt JR. Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer. Oncology 2001;61(suppl l):30-34.
15. Stupp R, Bodmer A, Duvoisin B et al. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 2001;61(suppl 1):35-41.
16. Pujol JL, von Pawel J, Tumolo S et al. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Oncology 2001;61(suppl l):47-54.
17. TM) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997;18(suppl 1):35.
18. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
19. von Pawel J, Gatzemeier U, Pujol JL et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
20. Ardizzoni A, Manegold C, Debruyne C et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003:9:143-150.
21. Lynch TJ Jr, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994;12:347-352.
22. Weitz JJ, Marschke RF Jr, Sloan JA et al. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000;28:157-162.
23. Mainwaring PN, Nicolson MC, Hickish T et al. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer 1997;76:1636-1639.
24. Kindler HL, Kris MG, Smith IE et al. Phase U trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol 1998;21:438-441.
25. White SC, Cheeseman S, Anderson H et al. A phase II study of oral topotecan in advanced non-small cell lung cancer: useful symptom palliation and 10 month median survival. Proc Am Soc Clin Oncol 1999;18:527a.
26. Cesano A, Lane SR, Poulin R et al. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999;15:1233-1238.
27. Johnson DH. Advanced NSCLC. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2003. http://www.fda.gov/cder/drug/ cancer_endpoints/johnson/index.htm, accessed 11/20/03.
28. Perez-Soler R, Fossella FV, Glisson BS et al. Phase U study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
29. Raymond E, Burris HA, Rowinsky EK et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann Oncol 1997;8:1003-1008.
30. Guarino MJ, Schneider CJ, Grubbs SS et al. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. The Oncologist 2002;7:509-515.
31. Joppert MG, Garfield DH, Gregurich MA et al. A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39:215-219.
32. Dowlati A, Levitan N, Gordon NH et al. Phase II and pharmacokinetic/ pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001;47:141-148.
33. Dobbs T, Eckardt J, Fanucchi M et al. Oral topotecan (OT) and intravenous paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a phase I/II study. Proc Am Soc Clin Oncol 2000;19:522a.
34. Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc Am Assoc Cancer Res 1992;33:431.
35. Rinaldi D, Lormand N, Brierre J et al. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer Invest 2001; 19:467-474.
36. Rinaldi DA, Lormand NA, Brierre IE et al. A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer 2002;95:1274-1278.
37. Larocca RV, Glisson S, Hargis J et al. Biweekly topotecan and gemcitabine in advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC): a phase I study. Proc Am Soc Clin Oncol 2003;22:680.
38. Kuzur ME, Jones S, Willcutt N et al. A phase I trial of weekly topotecan and docetaxel. Proc Am Soc Clin Oncol 2003;22:706.
39. Stewart DI, Raaphorst GP, Yau J et al. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 1996;14:115-130.